Abbott Laboratories

More Details of Abbott Laboratories Company

Abbott Laboratories is a global healthcare company. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. It serves people in more than 160 countries.

Company Info

Company codeABT

Company nameAbbott Laboratories

IPO dateMar 01, 1937

Founded at1900

CEOMr. Robert B. Ford

Number of employees114000

Security typeOrdinary Share

Fiscal year-endMar 01

Address100 Abbott Park Road

CityABBOTT PARK

Stock exchangeNYSE Consolidated

CountryUnited States of America

Postal code60064-3500

Phone12246676100

Websitehttps://www.abbott.com

Company codeABT

IPO dateMar 01, 1937

Founded at1900

Company Executives

Name

Name/Position

Position

Shareholding

Change

Mr. Daniel J. Starks

Independent Director

6.73M

--

Mr. Hubert L. Allen

Executive Vice President, General Counsel, Secretary

191.90K

+3.84%

Mr. Daniel Gesua Sive Salvadori

Executive Vice President, Group President - Established Pharmaceuticals and Nutritional Products

133.77K

+6.42%

Ms. Mary K. Moreland

Executive Vice President - Human Resources

95.58K

-0.82%

Ms. Lisa D. Earnhardt

Executive Vice President, Group President - Medical Devices

71.93K

--

Mr. Louis H. (Lou) Morrone

Executive Vice President - Core Diagnostics

66.88K

-1.63%

Mr. Philip P. Boudreau

Chief Financial Officer, Executive Vice President - Finance

56.91K

+44.72%

Dr. Robert J. Alpern, M.D.

Independent Director

39.16K

--

Ms. Nancy Mckinstry

Lead Independent Director

37.09K

--

Ms. Sally E. Blount, Ph.D.

Independent Director

35.02K

--

Name

Name/Position

Position

Shareholding

Change

Mr. Daniel J. Starks

Independent Director

6.73M

--

Mr. Hubert L. Allen

Executive Vice President, General Counsel, Secretary

191.90K

+3.84%

Mr. Daniel Gesua Sive Salvadori

Executive Vice President, Group President - Established Pharmaceuticals and Nutritional Products

133.77K

+6.42%

Ms. Mary K. Moreland

Executive Vice President - Human Resources

95.58K

-0.82%

Ms. Lisa D. Earnhardt

Executive Vice President, Group President - Medical Devices

71.93K

--

Mr. Louis H. (Lou) Morrone

Executive Vice President - Core Diagnostics

66.88K

-1.63%

Revenue Breakdown

Currency: USDUpdate time: Sun, Apr 6

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

By BusinessUSD

Name

Revenue

Proportion

Diabetes Care

6.80B

16.22%

Core Laboratory

5.24B

12.48%

Adult Nutritionals

4.39B

10.46%

Pediatric Nutritionals

4.02B

9.59%

Key Emerging Markets

3.86B

9.20%

Other

17.64B

42.05%

By RegionUSD

Name

Revenue

Proportion

United States

16.32B

38.91%

All other Countries

14.85B

35.39%

Germany

2.54B

6.05%

China

2.11B

5.04%

India

1.82B

4.33%

Other

4.31B

10.28%

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

Diabetes Care

6.80B

16.22%

Core Laboratory

5.24B

12.48%

Adult Nutritionals

4.39B

10.46%

Pediatric Nutritionals

4.02B

9.59%

Key Emerging Markets

3.86B

9.20%

Other

17.64B

42.05%

Shareholder

Update time: Sun, Feb 9

Shareholder Statistics

Type

Shareholder Statistics

Shareholder

Proportion

The Vanguard Group, Inc.

9.68%

BlackRock Institutional Trust Company, N.A.

5.02%

State Street Global Advisors (US)

4.45%

Capital International Investors

3.92%

Capital Research Global Investors

3.12%

Other

73.81%

Shareholder Statistics

Shareholder

Proportion

The Vanguard Group, Inc.

9.68%

BlackRock Institutional Trust Company, N.A.

5.02%

State Street Global Advisors (US)

4.45%

Capital International Investors

3.92%

Capital Research Global Investors

3.12%

Other

73.81%

Type

Shareholder

Proportion

Investment Advisor

35.54%

Investment Advisor/Hedge Fund

32.70%

Research Firm

3.26%

Pension Fund

2.27%

Bank and Trust

2.14%

Sovereign Wealth Fund

1.31%

Insurance Company

0.99%

Hedge Fund

0.89%

Individual Investor

0.48%

Other

20.43%

Institutional Shareholding

Update time: Sun, Jan 19

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q1

4447

1.39B

80.34%

+21.52M

2024Q4

4535

1.39B

80.22%

+15.89M

2024Q3

4391

1.36B

78.29%

-11.85M

2024Q2

4400

1.36B

78.24%

-7.03M

2024Q1

4402

1.35B

77.67%

-9.71M

2023Q4

4429

1.35B

77.56%

-11.05M

2023Q3

4298

1.34B

77.39%

-25.33M

2023Q2

4297

1.35B

77.60%

-13.55M

2023Q1

4281

1.35B

77.46%

-8.61M

2022Q4

4258

1.34B

76.84%

-15.37M

Shareholder Activity

Name

Shares Held

Proportion

Change

Chg %

Date

The Vanguard Group, Inc.

167.89M

9.68%

+762.54K

+0.46%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

87.07M

5.02%

+811.85K

+0.94%

Dec 31, 2024

State Street Global Advisors (US)

77.17M

4.45%

+447.25K

+0.58%

Dec 31, 2024

Capital International Investors

67.97M

3.92%

+2.23M

+3.39%

Dec 31, 2024

Capital Research Global Investors

54.10M

3.12%

+795.07K

+1.49%

Dec 31, 2024

Geode Capital Management, L.L.C.

35.67M

2.06%

+765.64K

+2.19%

Dec 31, 2024

Wellington Management Company, LLP

26.39M

1.52%

+581.33K

+2.25%

Dec 31, 2024

JP Morgan Asset Management

25.13M

1.45%

+5.11M

+25.51%

Dec 31, 2024

Norges Bank Investment Management (NBIM)

20.98M

1.21%

+626.72K

+3.08%

Dec 31, 2024

Wells Fargo Advisors

15.25M

0.88%

-105.40K

-0.69%

Dec 31, 2024

Related ETFs

Update time: Sat, Apr 5

Name

Proportion

iShares U.S. Medical Devices ETF

17.41%

Invesco Pharmaceuticals ETF

5.78%

Goldman Sachs Future Health Care Equity ETF

5.19%

NYLI Healthy Hearts ETF

4.78%

Polen Capital Global Growth ETF

4.77%

AdvisorShares Focused Equity ETF

4.63%

Proshares Ultra Health Care

4.32%

Health Care Select Sector SPDR Fund

4.24%

iShares U.S. Healthcare ETF

4.15%

Fidelity MSCI Health Care Index ETF

3.85%

iShares U.S. Medical Devices ETF

Proportion17.41%

Invesco Pharmaceuticals ETF

Proportion5.78%

Goldman Sachs Future Health Care Equity ETF

Proportion5.19%

NYLI Healthy Hearts ETF

Proportion4.78%

Polen Capital Global Growth ETF

Proportion4.77%

AdvisorShares Focused Equity ETF

Proportion4.63%

Proshares Ultra Health Care

Proportion4.32%

Health Care Select Sector SPDR Fund

Proportion4.24%

iShares U.S. Healthcare ETF

Proportion4.15%

Fidelity MSCI Health Care Index ETF

Proportion3.85%

Dividend

A total of 16.46B USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

Dec 13, 2024

ABT.NB Interim Cash Dividend of gross USD 0.59 paid on Feb 14, 2025 going ex on Jan 15, 2025 with reinvestment option

Jan 15, 2025

Feb 14, 2025

Jan 15, 2025

Sep 19, 2024

ABT.NB Final Cash Dividend of gross USD 0.55 paid on Nov 15, 2024 going ex on Oct 15, 2024

Oct 15, 2024

Nov 15, 2024

Oct 15, 2024

Jun 15, 2024

ABT.NB Interim Cash Dividend of gross USD 0.55 paid on Aug 15, 2024 going ex on Jul 15, 2024 with reinvestment option

Jul 15, 2024

Aug 15, 2024

Jul 15, 2024

Feb 16, 2024

ABT.NB Interim Cash Dividend of gross USD 0.55 paid on May 15, 2024 going ex on Apr 12, 2024

Apr 15, 2024

May 15, 2024

Apr 12, 2024

Dec 15, 2023

ABT.NB Interim Cash Dividend of gross USD 0.55 paid on Feb 15, 2024 going ex on Jan 11, 2024 with reinvestment option

Jan 12, 2024

Feb 15, 2024

Jan 11, 2024

Sep 21, 2023

ABT.NB Final Cash Dividend of gross USD 0.51 paid on Nov 15, 2023 going ex on Oct 12, 2023 with reinvestment option

Oct 13, 2023

Nov 15, 2023

Oct 12, 2023

Jun 09, 2023

ABT.NB Interim Cash Dividend of gross USD 0.51 paid on Aug 15, 2023 going ex on Jul 13, 2023 with reinvestment option

Jul 14, 2023

Aug 15, 2023

Jul 13, 2023

Feb 17, 2023

ABT.NB Interim Cash Dividend of gross USD 0.51 paid on May 15, 2023 going ex on Apr 13, 2023 with reinvestment option

Apr 14, 2023

May 15, 2023

Apr 13, 2023

Dec 09, 2022

ABT.NB Interim Cash Dividend of gross USD 0.51 paid on Feb 15, 2023 going ex on Jan 12, 2023 with reinvestment option

Jan 13, 2023

Feb 15, 2023

Jan 12, 2023

Sep 15, 2022

ABT.NB Final Cash Dividend of gross USD 0.47 paid on Nov 15, 2022 going ex on Oct 13, 2022 with reinvestment option

Oct 14, 2022

Nov 15, 2022

Oct 13, 2022

Stock Split

Date

Type

Ratio

No Data

Date

Type

Ratio

No Data

130.980USD

Abbott Laboratories

130.980

Overview

Company